Tamer Hellou

Dr. Tamer Hellou

Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
Tamer HellouTamer Hellou
Tamer Hellou
OCOmri Cohen
Omri Cohen
AAAbraham Avigdor
Abraham Avigdor
IAIrina Amitai
Irina Amitai
ASAvichai Shimoni
Avichai Shimoni
DMDrorit Merkel
Drorit Merkel

22 July 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
ADAmir Dagan
Amir Dagan
SDShani Dahan
Shani Dahan
ASAsaf Shemer
Asaf Shemer
PLPnina Langevitz
Pnina Langevitz
Tamer HellouTamer Hellou
Tamer Hellou
OSOra Shovman
Ora Shovman

17 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Tamer HellouTamer Hellou
Tamer Hellou
GDGuy Dumanis
Guy Dumanis
ABArwa Badarna
Arwa Badarna
GSGad Segal
Gad Segal
Background: Chronic lymphocytic leukemia (CLL) is one of the most common hematologic malignancies, especially among elderlies. Several prognostic scores are available that utilize the characteristics of patients’ blood counts and cytogenetic anomalies—all are features of the disease rather than of the patient. Addressing the route of personalized rather than precise medicine, we refer to the assessment of patients’ status of sarcopenia and frailty. Low alanine aminotransferase (ALT) was already shown to function as a surrogate marker for sarcopenia and frailty. We decided to find a possible correlation between low ALT values and poor prognosis of CLL patients. Patients and Methods: This is a retrospective cohort study of CLL patients treated in a large, tertiary medical center, as outpatients or inpatients. Their frailty status was evaluated in a retrospective manner. We defined patients with ALT below 12 IU/L as frail and divided our cohort into two groups including a low ALT level group (ALT < 12) and a normal ALT level group (ALT ≥ 12). Results: Overall, our final analysis included 716 CLL patients, of which 161 (22.5%) had ALT levels lower than 12 IU/L. There was no significant difference in patients’ age between the two groups. Patients with the low ALT had a lower hemoglobin concentration (median 10.8 g/dL [IQR = 2.7] vs. 12.2 [IQR = 3.1]; p < 0.001) and a higher proportion of patients were classified as Binet C score [48.4% vs. 31.1%]; p < 0.001). Frail CLL patients’ survival was significantly shorter when compared to non-frail patients, in both the univariate [HR = 1.6 [95% confidence interval, CI 1.23, 2.0]; p < 0.01] and multivariate analyses [HR = 1.3 [95% CI 1.0, 1.7]; p = 0.03]. Conclusions: Sarcopenia and frailty assessment, based on blood ALT measurements, could potentially point out differences in CLL patients’ prognoses. Such assessment could serve the purpose of treatment personalization of CLL patients.

27 December 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
Tamer HellouTamer Hellou
Tamer Hellou
SKShaji K. Kumar
Shaji K. Kumar
SASamhar Samer Alouch
Samhar Samer Alouch
AAAdrian Almodovar-Diaz
Adrian Almodovar-Diaz
ADAngela Dispenzieri
Angela Dispenzieri
WGWilson I. Gonsalves
Wilson I. Gonsalves

13 April 2023 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Open access
PDF file
LMLiron Miller
Liron Miller
MFMor Freed-Freundlich
Mor Freed-Freundlich
ASAvichai Shimoni
Avichai Shimoni
Tamer HellouTamer Hellou
Tamer Hellou
AAAbraham Avigdor
Abraham Avigdor
DMDrorit Merkel
Drorit Merkel
Introduction: Blood product transfusion retains a critical role in the supportive care of patients with acute myeloid leukemia (AML). Whereas previous studies have shown increased transfusion dependency to portend inferior outcome, predictive factors of an increased transfusion burden and the prognostic impact of transfusion support have not been assessed recently. Methods/Patients: We performed a retrospective analysis on a recent cohort of patients given intensive induction chemotherapy in 2014–2022. Results: The analysis comprised 180 patients with a median age of 57 years with 80% designated as de novo AML. Fifty-four patients (31%) were FLT3-ITD mutated, and 73 patients (42%) harbored NPM1. Favorable risk and intermediate risk ELN 2017 patients accounted for 43% and 34% of patients, respectively. The median number of red blood cell (RBC) and platelet units given during induction were 9 and 7 units, respectively. Seventeen patients (9%) received cryoprecipitate, and fresh frozen plasma (FFP) was given to 12 patients (7%). Lower initial hemoglobin and platelet levels were predictive of increased use of RBC (p < 0.0001) and platelet transfusions (p < 0.0001). FFP was significantly associated with induction related mortality (42% vs. 5%; p < 0.0001) and with FLT3-ITD (72% vs. 28%; p = 0.004). Blood group AB experienced improved mean overall survival compared to blood group O patients (4.1 years vs. 2.8 years; p = 0.025). In multivariate analysis, increased number of FFP (hazard ratio [HR], 4.23; 95% confidence interval [CI], 2.1–8.6; p < 0.001) and RBC units (HR, 1.8; 95% CI, 1.2–2.8; p = 0.008) given was associated with inferior survival. Conclusion: Transfusion needs during induction crucially impact the clinical trajectory of AML patients.

29 September 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
Tamer HellouTamer Hellou
Tamer Hellou
DPDaniel G. Packard
Daniel G. Packard
SASuheil Albert Atallah-Yunes
Suheil Albert Atallah-Yunes
AOAhauve M. Orusa
Ahauve M. Orusa
SSShinichiro Suzuki
Shinichiro Suzuki
MGMorie A. Gertz
Morie A. Gertz
Autologous stem cell transplantation (ASCT) is a key therapeutic strategy for many patients diagnosed with multiple myeloma (MM), yet early relapses post-transplant remains a major clinical challenge. The plasma cell proliferation (PCPRO) test, which quantifies the proportion of clonal plasma cells in the bone marrow in S-phase (S-phase%) offers a scalable alternative to measuring their proliferation rate compared to the older plasma cell labeling index (PCLI) assay. The impact of the S-phase% in residual clonal plasma cells at the time of ASCT is not clear. We retrospectively analyzed MM patients undergoing an ASCT within one year of diagnosis at Mayo Clinic between January 2013-August 2024. The S-phase% was determined by multiparametric flow cytometry. Patients were grouped into S-phase <2%, ≥2%, or non-assessable, reflecting low numbers of clonal plasma cells at time of ASCT. Among 1,136 patients, 372 had an S-phase <2%, 142 had an S-phase of ≥2% and 622 had non-assessable S-phase. Patients with S-phase ≥2% had higher rates of high-risk cytogenetics, ISS stage III, and elevated creatinine. Median progression-free survival (PFS) and overall survival (OS) from time of ASCT were 26 months and 57 months for patients with S-phase ≥2%, compared to 47 months and not reached for those with S-phase <2%. (P < 0.0001 for both PFS and OS). Patients with non-assessable S-phase, had the most favorable outcomes. In conclusion, our results show that S-phase% at the time of ASCT is a significant prognostic marker in MM. Notably, patients with S-phase ≥5%, and especially ≥10%, had extremely poor outcomes (median PFS of 13 and 3.5 months, respectively), identifying a functionally high-risk group that may derive little or no benefit from standard ASCT. This poor prognostic factor should lead to consideration of alternative strategies including enrollment in clinical trials evaluating novel immunotherapies such as CAR T-cells or T-cell engagers as part of first-line therapy.